Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 259

Results For "AP"

8342 News Found

Glenmark receives ANDA approval for Icatibant Injection
News | May 25, 2021

Glenmark receives ANDA approval for Icatibant Injection

This marks Glenmark's first synthetic decapeptide injectable approval


Everest Organics launches 'Posaconazole' API
News | May 25, 2021

Everest Organics launches 'Posaconazole' API

Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients


NATCO Pharma receives USFDA approval for Lenalidomide capsules
Policy | May 24, 2021

NATCO Pharma receives USFDA approval for Lenalidomide capsules

NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.


Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella
People | May 23, 2021

Bharat Biotech ramping up manufacturing capacity to 70 Cr doses: Dr. Raches Ella

We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity


India's first indigenous COVID-19 RT-PCR testing kit approved
News | May 21, 2021

India's first indigenous COVID-19 RT-PCR testing kit approved

This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips


Alembic gets USFDA approval for Lurasidone Hydrochloride tablets
News | May 15, 2021

Alembic gets USFDA approval for Lurasidone Hydrochloride tablets

Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder


Gap between two doses of Covishield extended; No extension for Covaxin
News | May 14, 2021

Gap between two doses of Covishield extended; No extension for Covaxin

The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield


COVAXIN phase II/III clinical trial approved for 2-18 years
News | May 13, 2021

COVAXIN phase II/III clinical trial approved for 2-18 years

BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years


Dr. Reddy's launches Ertapenem in US
News | May 12, 2021

Dr. Reddy's launches Ertapenem in US

The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health


DCGI approves anti-COVID drug developed by DRDO
Policy | May 10, 2021

DCGI approves anti-COVID drug developed by DRDO

The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production